The Bacterial Symbiont Wolbachia Induces Resistance to RNA Viral Infections in Drosophila melanogaster
L Teixeira, Á Ferreira, M Ashburner - PLoS biology, 2008 - journals.plos.org
Wolbachia are vertically transmitted, obligatory intracellular bacteria that infect a great number
of species of arthropods and nematodes. In insects, they are mainly known for disrupting …
of species of arthropods and nematodes. In insects, they are mainly known for disrupting …
Turning subjective into objective: the BCCT. core software for evaluation of cosmetic results in breast cancer conservative treatment
…, D Macmillan, MP Mano, L Regolo, J Rosa, L Teixeira… - The Breast, 2007 - Elsevier
Twelve expert observers from nine different countries convened in a workshop to evaluate
the validity of the Breast Cancer Conservative Treatment. Cosmetic results (BCCT.core) …
the validity of the Breast Cancer Conservative Treatment. Cosmetic results (BCCT.core) …
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …
Background Pembrolizumab monotherapy showed durable antitumour activity and manageable
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
Diamide insecticides: Global efforts to address insect resistance stewardship challenges
LA Teixeira, JT Andaloro - Pesticide Biochemistry and Physiology, 2013 - Elsevier
The diamides are the most recent addition to the limited number of insecticide classes with
specific target site activity that are highly efficacious, control a wide pest spectrum, and have a …
specific target site activity that are highly efficacious, control a wide pest spectrum, and have a …
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
…, S Siena, J Tabernero, L Teixeira… - Journal of the …, 2015 - academic.oup.com
Background: Positive findings from the phase III MPACT trial led to the regulatory approval
of nab-paclitaxel plus gemcitabine as a treatment option for patients with metastatic …
of nab-paclitaxel plus gemcitabine as a treatment option for patients with metastatic …
FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity
…, P Froguel, CJ Owen, SHS Pearce, L Teixeira… - Nature …, 2007 - nature.com
Naturally occurring variation in gene copy number is increasingly recognized as a heritable
source of susceptibility to genetically complex diseases. Here we report strong association …
source of susceptibility to genetically complex diseases. Here we report strong association …
Designing tablet-based games for seniors: the example of CogniPlay, a cognitive gaming platform
This paper describes the analysis and design of a tablet-based gaming platform for seniors
that promotes their quality-of-life and well-being by incorporating cognitive training …
that promotes their quality-of-life and well-being by incorporating cognitive training …
Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2
C Dodé, L Teixeira, J Levilliers, C Fouveaut… - PLoS …, 2006 - journals.plos.org
Kallmann syndrome combines anosmia, related to defective olfactory bulb morphogenesis,
and hypogonadism due to gonadotropin-releasing hormone deficiency. Loss-of-function …
and hypogonadism due to gonadotropin-releasing hormone deficiency. Loss-of-function …
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA …
…, JE PLAZA, F CLATOT, L TEIXEIRA… - The Lancet …, 2022 - thelancet.com
Background In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired
resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which …
resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which …
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the …
…, J Tabernero, C Boni, JB Bachet, L Teixeira… - Journal of clinical …, 2012 - ascopubs.org
Purpose Oxaliplatin combined with fluoropyrimidine improves survival in patients with stage
III colon cancer. However, adjuvant chemotherapy with oxaliplatin is controversial in stage II …
III colon cancer. However, adjuvant chemotherapy with oxaliplatin is controversial in stage II …